View Older Stories View More Recent Stories
-
Aprecia Pharmaceuticals Secures up to $30 Million from Hercules Capital
-
Deerfield Announces Lead Investment in Visionary Anti-Fibrotic Company Blade Therapeutics
-
Blade Therapeutics Raises $45 Million Series B Financing with Unparalleled Syndicate of VCs and Strategic Pharma Investors
-
Form 4 eHealth, Inc. For: Jun 06 Filed by: DEERFIELD MANAGEMENT CO
-
Flynn's Deerfield Management Raises Stake in Relypsa (RLYP) to 5.28%
-
Form 13F-HR DEERFIELD MANAGEMENT CO For: Mar 31
-
Neos Therapeutics Announces Closing of $60 Million Term Debt Financing and First Quarter 2016 Financial Results
-
Windtree Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Updates
-
Deerfield Supports Patient Care Advancing Ophthalmology Company Graybug Vision
-
Graybug Vision Announces $44.5 Million Series B Financing
-
Homology Medicines Emerges with Next Generation Gene Editing Technology Driven by Industry-leading Team in Rare Diseases
-
Deerfield Leads $34 Million Investment in Lumos Pharma
-
Lumos Pharma Raises $34 Million in Series B Financing
-
Discovery Labs Reports Fourth Quarter 2015 Financial Results and Provides Business Updates
-
Recovery Centers of America Acquires Lighthouse Recovery Center in Mays Landing, N.J.
-
AAC Holdings, Inc. Reports Fourth Quarter and Full Year 2015 Results
-
Synlogic Secures $40 Million in Series B Financing
-
Form 4 XENOPORT INC For: Feb 11 Filed by: DEERFIELD MANAGEMENT CO
-
Form 13F-HR DEERFIELD MANAGEMENT CO For: Dec 31
-
Form 4 AveXis, Inc. For: Feb 10 Filed by: DEERFIELD MANAGEMENT CO
-
ESSA Pharma Inc. reports financial results for the first quarter ended December 31, 2015
-
Form 4 ZAFGEN, INC. For: Feb 09 Filed by: DEERFIELD MANAGEMENT CO
-
KemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021
-
Flamel Technologies Acquires FSC Pediatrics
-
Form 4 Editas Medicine, Inc. For: Feb 08 Filed by: DEERFIELD MANAGEMENT CO
-
KemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021
-
Deerfield Management and Oxeon Unlock the Power of Women in the Boardroom
-
Deerfield Finances Pioneer in 3D Printing for Pharmaceuticals
-
Aprecia Pharmaceuticals Set to Advance 3D Printed Drug Pipeline with Completion of $35 Million Financing Led by Deerfield Management
-
Nuo Therapeutics Inc. Commences Voluntary Chapter 11 Business Reorganization
-
ESSA Pharma Announces Closing of US$15 Million Private Placement
-
Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing
-
Nuo Therapeutics Announces Senior Management Change and Provides Limited Corporate Update
-
Deerfield Advances Healthcare Through the Publication of Novel Findings
-
Xeris Pharmaceuticals Announces $41 Million Series C Financing
-
ESSA Pharma (EPIX) Plans $15M Units Private Placement
-
ESSA Pharma announces proposed US$15 million private placement
-
Nuo Therapeutics Announces Execution of Third Limited Consent With Deerfield Management Through January 7, 2016
-
Deerfield Announces Partnership with Recovery Centers of America
-
Deerfield Leads Series A in Hallux, Inc.
-
Recovery Centers of America Raises $231.5 Million to Revolutionize Addiction Treatment and Behavioral Healthcare and Become One of the World’s Largest Providers by Bringing Comprehensive Centers for
-
Hallux Announces Closing of $7.1 Million Series A Financing
-
Nuo Therapeutics Announces Appointment of Chief Restructuring Officer
-
Form 4 DEERFIELD MANAGEMENT CO For: Dec 04 Filed by: ALIMERA SCIENCES INC
-
Nuo Therapeutics Announces Execution of Second Limited Consent With Deerfield Management Through December 17, 2015
-
Nuo Therapeutics Announces Execution of Second Limited Consent With Deerfield Management Through December 17, 2015
-
Fractyl Announces Completion of $57 Million Series C Investment
-
Form 13F-HR DEERFIELD MANAGEMENT CO For: Sep 30
-
Nuo Therapeutics Announces Execution of Limited Consent With Deerfield Management Through December 4, 2015
-
Nuo Therapeutics Announces 3rd Quarter 2015 Financial Results

